65795-37-1

Basic information

• Product Name: 7H-PYRROLO[3,2-F]QUINAZOLINE-1,3-DIAMINE
• Synonyms: 7H-PYRROLO[3,2-F]QUINAZOLINE-1,3-DIAMINE;Aids029297;Aids-029297;Nsc339578
• CAS NO: 65795-37-1
• Molecular Formula: C₁₀H₉N₅
• Molecular Weight: 199.21
• Mol File: 65795-37-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 620.1 °C at 760 mmHg
• Flash Point: 365.3 °C
• Appearance: /
• Density: 1.568 g/cm³
• Vapor Pressure: 2.67E-15mmHg at 25°C
• Refractive Index: 1.942
• PKA: 14.79±0.50(Predicted)
• CAS DataBase Reference: 7H-PYRROLO[3,2-F]QUINAZOLINE-1,3-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7H-PYRROLO[3,2-F]QUINAZOLINE-1,3-DIAMINE(65795-37-1)
• EPA Substance Registry System: 7H-PYRROLO[3,2-F]QUINAZOLINE-1,3-DIAMINE(65795-37-1)

Safety Data

• Hazardous Substances Data: 65795-37-1(Hazardous Substances Data)

Usage

Description

7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine is a heterocyclic compound belonging to the pyrroloquinazoline class. It features a nitrogenous base derivative with a pyrrolo[3,2-f]quinazoline backbone and amine groups at positions 1 and 3. 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine is of interest in pharmaceutical applications due to its structural resemblance to nucleic acid bases, enabling interactions with DNA or RNA. Additionally, it may serve as a building block in the synthesis of biologically active molecules, making it a valuable subject for research in medicinal chemistry and drug development.

Uses

Used in Pharmaceutical Industry:
7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine is used as a potential pharmaceutical agent for its ability to interact with DNA or RNA. Its structural similarity to nucleic acid bases allows it to potentially modulate gene expression or target specific genetic sequences, offering therapeutic benefits in various diseases.
Used in Medicinal Chemistry Research:
7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine is used as a subject of interest in medicinal chemistry research due to its unique properties and reactivity. Its potential as a building block in the synthesis of biologically active molecules makes it a valuable compound for the development of new drugs and therapeutic agents.
Used in Drug Development:
7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine is used in drug development as a promising candidate for the creation of novel therapeutic agents. Its ability to interact with nucleic acids and serve as a building block in the synthesis of biologically active molecules positions it as a key component in the design and development of new drugs with potential applications in various medical fields.

InChI:InChI=1/C10H9N5/c11-9-8-5-3-4-13-6(5)1-2-7(8)14-10(12)15-9/h1-4,13H,(H4,11,12,14,15)

Upstream product

• 150057-70-8 N-cyano-N'-(1H-indol-5-yl)guanidine 
• 5192-03-0 5-amino-1H-indole 
• 161464-96-6 N-cyano-N'-(1H-indol-5-yl)guanidine 

Downstream Products

• 65795-63-3 7-(4-isopropyl-benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine 
• 65795-65-5 7-(4-methylsulfanyl-benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine 
• 65795-64-4 7-(4-tert-butyl-benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine 
• 65795-73-5 7-(4-ethoxy-benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine 
• 79851-92-6 7-[(2,5-Dimethylphenyl)Sulfonyl]-7H-Pyrrolo-[3,2-f]Quinazoline-1,3-Diamine 
• 65795-38-2 7-benzyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine 
• 65796-07-8 7-(4-Carboxybenzyl)-7H-pyrrolo[3,2-f]-quinazoline-1,3-diamine, sodium salt 
• 65796-08-9 4-(1,3-diamino-pyrrolo[3,2-f]quinazolin-7-yl)-benzonitrile 
• 65796-01-2 7-(4-trifluoromethoxy-benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine 
• 75369-35-6 7-[(2,4-Dichlorophenyl)methyl]-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine 

Relevant articles and documents

PYRROLOQUINAZOLINE COMPOUNDS

Disclosed herein are acylated derivatives of 7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and pharmaceutical compositions comprising said derivatives.

High-affinity inhibitors of dihydrofolate reductase: Antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size

A series of 7,8-dialkylpyrrolo[3,2-f]quinazolines were prepared as inhibitors of dihydrofolate reductase (DHFR). On the basis of an apparent inverse relationship between compound size and antifungal activity, the compounds were designed to be relatively small and compact. Inhibitor design was aided by a GRID analysis of the three-dimensional structure of Candida albicans DHFR, which suggested that relatively small, branched alkyl groups at the 7- and 8-positions of the pyrroloquinazoline ring system would provide optimal interactions with a hydrophobic region of the protein. The compounds were potent inhibitors of fungal and human DHFR, with K(i) values as low as 7.1 and 0.1 pM, respectively, and were highly active against C. albicans and an array of tumor cell lines. In contrast to known lipophilic inhibitors of DHFR such as trimetrexate and piritrexim, members of this series of pyrroloquinazolines were not susceptible to P-glycoprotein-mediated multidrug resistance and also showed significant distribution into lung and brain tissue. The compounds were active in lung and brain tumor models and displayed in vivo activity against Pneumocystis carinii and C. albicans.

7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines

7-(Substituted)-pyrrolo[3,2-f]quinazoline-1,3-diamines possess antibacterial activity in vitro. The invention also provides compounds having in vivo activity against malarial infections.